Translational Oncology
Overview
Translational Oncology is a peer-reviewed journal that focuses on bridging the gap between basic science and clinical research in the field of oncology. It publishes cutting-edge studies that aim to translate laboratory discoveries into practical applications for cancer prevention, diagnosis, and treatment. The journal serves as a platform for researchers, clinicians, and policymakers to share their findings and insights, ultimately advancing the understanding and management of cancer.
Details
Details
Abbr.
Transl Oncol
Start
2007
End
Continuing
e-ISSN
1936-5233
Country
United States
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 4950
72
SJR / Ranks: 2603
1263
CiteScore / Ranks: 2750
7.20
JIF / Ranks: 1573
5.0
Recent Articles
21.
Dong J, Fu C, Li M, Wang Z, Li B
Transl Oncol
. 2025 Feb;
54:102326.
PMID: 40014978
Objective: This study aims to elucidate the impact of repeated whole-body computed tomography (CT) scans on systemic immunity, the tumor immune microenvironment, and tumor control. This inquiry was prompted by...
22.
Rostom M, Rashwan A, Sotiropoulou C, Hozayen S, Abdelhamid A, Abdelhalim M, et al.
Transl Oncol
. 2025 Feb;
54:102329.
PMID: 40014977
Long non-coding RNAs (LncRNAs) have emerged as intriguing players in cellular regulation, challenging the traditional view of non-coding RNAs as mere "dark genome". Non-coding DNA makes up most of the...
23.
Zhang S, Li X, Xiahou Z, Chen A, Sun R, Liu C, et al.
Transl Oncol
. 2025 Feb;
54:102295.
PMID: 40014976
Objective: In both industrialized and developing nations worldwide, lung adenocarcinoma is one of the deadliest malignant tumors and the primary cause of cancer-related deaths. Its cellular heterogeneity is unclear to...
24.
Wang J, Wang Y, Zhou H, Yu G, Xu H, Gao D, et al.
Transl Oncol
. 2025 Feb;
54:102320.
PMID: 39999729
Castration-resistant prostate cancer (CRPC) marks the advanced phase of prostate malignancy, manifested through two principal subtypes: castration-resistant adenocarcinoma (CRPC-adeno) and neuroendocrine prostate cancer (NEPC). This study aims to identify unique...
25.
Mauro F, Bruni S, Dupont A, Schey A, Badalini A, Inurrigarro G, et al.
Transl Oncol
. 2025 Feb;
54:102325.
PMID: 39987883
Purpose: Triple-negative breast cancer (TNBC) has the worst prognosis among breast cancers. Immunotherapy is a therapeutic option, but there is no biomarker to guide promising combination treatments. Mucin 4 (MUC4)...
26.
He L, Jiao N, Bao X, Wu Y, Qian X, He W, et al.
Transl Oncol
. 2025 Feb;
54:102322.
PMID: 39986192
Background: Cellular immunotherapy exhibits promise in treating blood tumors. However, its application for solid tumors is impeded by their heterogeneity and complex microenvironments. The development of individualized multitarget therapy may...
27.
Li Y, Jiang Y, Tong R, Ding B, Ge J, Du K, et al.
Transl Oncol
. 2025 Feb;
54:102327.
PMID: 39986191
Intrahepatic cholangiocarcinoma (ICC) is an aggressive cancer with an extremely poor prognosis, highlighting the urgent need for new treatment options. Recent studies increasingly suggest that the Forkhead box M1 (FOXM1)...
28.
Kang Y, Meng Y, Jin J, Dai Y, Li F, Chen N, et al.
Transl Oncol
. 2025 Feb;
54:102330.
PMID: 39986190
Background: Breast cancer is one of the most prevalent malignant tumors in women. Mitochondria, essential for cellular function, have altered metabolic activity in cancer cells, influencing tumor regulation and clinical...
29.
Hu A, Zhang L, Cao L, Li H, Huang R, Zhou X, et al.
Transl Oncol
. 2025 Feb;
54:102321.
PMID: 39986189
Background: RING finger protein 135 (RNF135) is identified as a regulator in certain cancer types. However, its role and molecular mechanisms in breast cancer are still unclear. Methods: Herein, we...
30.
M2-like tumor-associated macrophages may promote tumor progression in malignant pleural mesothelioma
Fukui T, Sumitomo R, Menju T, Kobayashi M, Sakai H, Date H
Transl Oncol
. 2025 Feb;
54:102324.
PMID: 39983469
Introduction: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with an unfavorable prognosis. Asbestos-activated macrophages may contribute to both oncogenesis and progression of MPM. This study aimed to clarify the...